SCHEMBL26686045

SCHEMBL26686045

Nc1n[nH]c2ccc(-c3ccnc(NC(=O)Nc4cccc(F)c4)c3)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 10/20 0.57
▸ LCK P06239 4/20 0.57
▸ FLT3 P36888 4/20 0.57
▸ KIT P10721 4/20 0.57
▸ LYN P07948 3/20 0.57
▸ FLT1 P17948 3/20 0.57
▸ FLT4 P35916 3/20 0.57
▸ BLK P51451 3/20 0.57
▸ FYN P06241 2/20 0.57
▸ CSF1R P07333 2/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ SRC P12931 1/20 0.57
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ NFKB2 Q00653 1/20 0.55
▸ RELA Q04206 1/20 0.55
▸ LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633305 1.00 KDR (0.57) KDRLCKFLT3KITLYN
SCHEMBL26686115 0.89 JAK2 (0.57) KDRLCKFLT3KITLYN
SCHEMBL30633403 0.89 JAK2 (0.57) KDRLCKFLT3KITLYN
SCHEMBL26685861 0.89 JAK2 (0.56) KDRLCKFLT3KITLYN
SCHEMBL30633352 0.89 JAK2 (0.56) KDRLCKFLT3KITLYN
SCHEMBL26685995 0.88 MAPK1 (0.49) KDRLCKFLT3KITLYN
SCHEMBL30633282 0.88 MAPK1 (0.49) KDRLCKFLT3KITLYN
SCHEMBL30633365 0.88 KDR (0.62) KDRLCKFLT3KITLYN
SCHEMBL26685808 0.88 KDR (0.62) KDRLCKFLT3KITLYN
SCHEMBL31420120 0.87 JAK2 (0.48) KDRLCKFLT3KITLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB KDR 2334/4885LCK 138/4885FLT3 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback